Apoptosis regulators (None applicable)

Apoptosis regulators represent a diverse collection of proteins and signaling molecules that control programmed cell death, a fundamental biological process essential for development, tissue homeostasis, and elimination of damaged or unwanted cells. This category encompasses multiple protein families working through interconnected pathways rather than constituting a single molecular target.\n\nThe regulatory network includes the BCL-2 protein family (approximately 20-25 members in humans), which serves as the central gatekeeper of the intrinsic mitochondrial apoptotic pathway. This family divides into three functional groups: multi-domain anti-apoptotic proteins (BCL-2, BCL-XL, BCL-W, MCL-1, BCL2A1/BFL-1, BCLB) that prevent cell death by maintaining mitochondrial membrane integrity; multi-domain pro-apoptotic effectors (BAX, BAK, BOK) that permeabilize mitochondrial membranes to release cytochrome c; and BH3-only pro-apoptotic proteins (BID, BIM, BAD, BIK, NOXA, PUMA, BMF, HRK) that sense cellular stress and either directly activate effectors or neutralize anti-apoptotic proteins. These family members interact through conserved BCL-2 homology (BH) domains consisting of stretches of up to 15 amino acids.\n\nThe caspase family of cysteine proteases serves as executioner enzymes, with initiator caspases (caspase-8 for extrinsic pathway, caspase-9 for intrinsic pathway) activating downstream executioner caspases (caspase-3, -6, -7) that dismantle cellular components. The death receptors (Fas/CD95, TRAIL-R1/DR4, TRAIL-R2/DR5, TNF receptors) at the cell surface initiate the extrinsic pathway upon ligand binding, recruiting adaptor proteins like FADD and activating caspase-8.\n\nCritical cross-talk exists between pathways, exemplified by caspase-8 cleavage of BID creating truncated BID (tBID) that engages mitochondria. The tumor suppressor p53 plays an important upstream regulatory role by modulating BCL-2 family protein expression, though exact mechanisms remain incompletely understood.\n\nIn disease contexts, dysregulation of apoptosis contributes significantly to pathology. Cancer cells frequently overexpress anti-apoptotic proteins (particularly BCL-2, BCL-XL, MCL-1) or lose pro-apoptotic function, enabling survival despite oncogenic stress and chemotherapy. Conversely, excessive apoptosis characterizes neurodegenerative diseases, myocardial infarction, liver diseases, sepsis, and spinal cord injury.\n\nTherapeutic strategies exploit this biology bidirectionally. For cancer, approaches include BCL-2 family inhibitors (BH3 mimetics), TRAIL receptor agonists (recombinant ligands or agonistic antibodies), and small molecules promoting caspase activation or interfering with protein-protein interactions that suppress apoptosis. For degenerative conditions, caspase inhibitors like z-VAD-fmk have shown protective effects in animal models of liver injury, arthritis, myocardial infarction, sepsis, and spinal cord injury.\n\nResistance mechanisms complicate therapy, including compensatory upregulation of alternative survival proteins, mutations in KRAS and PI3K/AKT/mTOR pathways that block apoptotic signaling, and variable expression of BCL-2 family members. Combination strategies targeting multiple nodes simultaneously or using MEK inhibitors with BCL-XL antagonists show promise for overcoming resistance.\n\nMicroRNAs add another regulatory layer, with specific miRNAs acting as pro- or anti-apoptotic factors by targeting apoptotic pathway mRNAs. Examples include miR-20a, miR-21, miR-34a, and let-7 family members affecting Fas/FasL, TNF-α, BCL-XL, and MCL-1 expression.\n\nThe field continues evolving with improved understanding of direct versus indirect activation models for BAX/BAK, development of more selective inhibitors, identification of predictive biomarkers, and recognition that successful therapy may require multitargeted approaches accounting for tumor genetic background and compensatory resistance mechanisms.

Other names

Programmed cell death regulatorsapoptotic proteinscell death regulatorsapoptosis pathway components

Pro-apoptotic mechanisms (for cancer treatment):\n- Direct activation of pro-apoptotic BCL-2 family members (BAX, BAK)\n- Inhibition of anti-apoptotic BCL-2 family proteins (BCL-2, BCL-XL, MCL-1, BCL-W, BFL-1/BCL2A1)\n- Activation of death receptors (extrinsic pathway initiation)\n- BH3 mimetics that displace pro-apoptotic proteins from anti-apoptotic proteins\n- Promotion of cytochrome c release from mitochondria\n- Facilitation of apoptosome formation\n- Caspase activation (caspase-8, caspase-9, executioner caspases-3, -6, -7)\n- Downregulation of c-FLIP (caspase-8 inhibitor)\n- Transcriptional induction of TRAIL receptors DR4 and DR5\n- Upregulation of pro-apoptotic molecules like caspase-8 and FADD\n\nAnti-apoptotic mechanisms (for degenerative diseases):\n- Caspase inhibition (broad spectrum or specific caspases)\n- Prevention of caspase-1-dependent inflammatory cytokine maturation (IL-1β, IL-18)\n- Blockade of death receptor-mediated injury\n- Protection of mitochondrial membrane integrity